Tandem Diabetes Care Analysts Boost Their Forecasts After Upbeat Q4 Results - Tandem Diabetes Care (NASDAQ:TNDM)

Financial Performance - Tandem Diabetes Care reported quarterly losses of 1 cent per share, outperforming the analyst consensus estimate of losses of 8 cents per share [1] - The company achieved quarterly sales of $290.400 million, exceeding the analyst consensus estimate of $277.029 million [1] Future Outlook - For FY2026, Tandem Diabetes Care projects sales between $1.065 billion and $1.085 billion, compared to market estimates of $1.103 billion [1] - The CEO highlighted that 2025 was a significant year with over $1 billion in worldwide sales and record gross margins, indicating a strong foundation for future growth [2] Market Reaction - Following the earnings announcement, Tandem Diabetes Care shares increased by 36%, reaching a trading price of $25.19 [2]